LY3023414 is a novel oral phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitor designed for advanced cancers, for which a phase II clinical study was completed in March 2020; however, little is known about its effect on bone modelling/remodelling. In this study, we aimed to explore the function of LY3023414 in bone modelling/remodelling.

中文翻译：

---

LY3023414通过PI3K / Akt / GSK3信号通路抑制成骨和破骨细胞生成。

LY3023414是一种新型口服磷脂酰肌醇3激酶（PI3K）/雷帕霉素（mTOR）双重抑制剂的哺乳动物靶标，设计用于晚期癌症，该药物的II期临床研究已于2020年3月完成；然而，关于其对骨骼建模/重塑的影响知之甚少。在这项研究中，我们旨在探索LY3023414在骨骼建模/重塑中的功能。